Navigation Links
PAREXEL Expands Alliance Network to Support Early Phase Patient Studies, Establishes Collaboration With University Hospitals Bristol NHS Foundation Trust
Date:1/23/2012

BOSTON, Jan. 23, 2012 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, announced today that it has established an alliance with University Hospitals Bristol National Health Service (NHS) Foundation Trust (UH Bristol), one of the largest specialist teaching and research hospital trusts in the United Kingdom. Through this agreement with UH Bristol, PAREXEL continues to expand its alliance network, which complements its dedicated team of experts and hospital-based Early Phase units, providing clients with access to diverse patient populations worldwide in key therapeutic areas.

"Our extensive, relevant experience and in-depth expertise, as well as global access to suitable patient populations, all contribute to our ability to assist clients with ever more complex early-phase trial design and execution. In doing so, our focus is to provide more efficient delivery of better, faster go/no-go decisions," said Sy Pretorius, M.D., M.S., M.B.A., Corporate Vice President and Worldwide Head of Early Phase.  "UH Bristol is an ideal alliance for us because of its experience in conducting clinical research, access to substantial patient populations, and work across multiple therapeutic areas."

Research Director at UH Bristol Professor David Wynick said:  "We believe this alliance furthers our objectives to develop collaborative and consultative research partnerships and support research of national and international excellence and innovation. We look forward to working with PAREXEL to expand our research portfolio for the benefit of patients."UH Bristol, the region's largest provider of medical and dental teaching, is a leading research center an
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. PAREXEL Announces Date of Second Quarter Fiscal Year 2012 Earnings Release and Conference Call
2. PAREXEL Strengthens Late Phase and Observational Research Capabilities With Expert Team to Help Biopharma Meet Commercialization Goals
3. PAREXEL Advances Early Phase CNS Research Capabilities With Leading Medical Imaging Technology
4. UCB and PAREXEL Sign Strategic Partnership Agreement
5. PAREXEL International to Present at Lazard Capital Markets Healthcare Conference and Citi Small/Mid Cap Conference
6. PAREXEL Commercialization Experts to Present Best-Practice Approaches for Demonstrating Product Value at ISPOR Annual European Congress
7. PAREXEL Reports First Quarter Fiscal Year 2012 Financial Results
8. PAREXEL Expands Commercialization Capabilities With Dedicated Team to Help Biopharma Companies Demonstrate Product Value
9. New PAREXEL Podcast Series to Deliver Clinical Development and Commercialization Thought Leadership
10. PAREXEL and National University of Singapore Establish Program in Singapore to Meet Increasing Demand in Asia for Clinical Research Talent
11. PAREXEL Announces Date of First Quarter Fiscal Year 2012 Earnings Release and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... de mayo de 2013  Volcano Corporation (NASDAQ: ... fabricante de herramientas de precisión para terapia guiadas ... la enfermedad vascular periférica y coronaria, anunció hoy ... enosine V asodilator I ndependent ... sesión de ensayo clínico hot line late breaking ...
(Date:5/23/2013)... OAKS, Calif. , May 23, 2013 Amgen ... Bank 38 th Annual  Healthcare Conference on Thursday, May ... Boston , beginning at 9:20 a.m. Eastern Daylight Time. ... Relations at Amgen, will present at the conference. Live audio ... on Amgen,s website, www.amgen.com , under Investors. A replay ...
(Date:5/23/2013)... RIVER EDGE, N.J. , May 23, 2013 /PRNewswire/ ... ), a commercial stage medical device company that develops ... the successful completion of its rights offering.  In addition, ... company,s March 2011 warrants expired on May 17, 2013. ... proceeds of $3.0 million from the rights offering.   A ...
Breaking Medicine Technology:Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
... WILMINGTON, Del. , April 30 ... and Drug Administration (FDA) has approved VIMOVO™ ... of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ... gastric ulcers in patients at risk of developing NSAID-associated ...
... The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine ... as its July 2010 "Stock to Study" and Gilead ... for investors, informational and educational use. , ... "The committee chose Teva Pharmaceutical Industries because of the tremendous ...
Cached Medicine Technology:FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 2FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 3FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 4FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 5FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 6FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 7FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 8FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 9BetterInvesting Magazine Releases July's Stock to Study and Undervalued Stock Choices for Investors' Informational and Educational Use 2BetterInvesting Magazine Releases July's Stock to Study and Undervalued Stock Choices for Investors' Informational and Educational Use 3
(Date:5/24/2013)... 25, 2013 Part guidebook, part memoir, ... a tried and true approach to meditation for the ... Mastering the 11th Step, the book outlines a comprehensive ... of the 11th step in any 12-step recovery programs ... drug dependence an ever-growing global health problem affecting the ...
(Date:5/24/2013)... 2013 Range Kleen Mfg. strives to “TCOTC.” ... Customer, from the President's desk to the Shipping Dock.” We ... integrity, and having passion while creating excellence and quality being ... company to do the right thing and what better way ... affected by devastation. , Throughout the year Range Kleen donates ...
(Date:5/24/2013)... New York, New York (PRWEB) May 24, 2013 ... from the 2010 DePuy hip recall continue to move ... reports. According to documents filed in California’s San ... had been seeking an expedited trial of her DePuy ... (Tilman v. DePuy Orthopaedics, Inc., et al., No. ...
(Date:5/24/2013)... 2013 ResortQuest Real Estate® is proud ... Feher team at the firm’s Bethany Beach location. , ... her home in 1975. Her real estate career began ... aspects of the real estate business - receptionist, cleaning ... years, a licensed sales associate. , “I am ...
(Date:5/24/2013)... research suggests a link between sleep duration and ... additional hour someone with insomnia sleeps is associated ... of moderate or high risk of suicide, according ... "We were surprised by the strength of ... study author, Linden Oliver, clinical research coordinator for ...
Breaking Medicine News(10 mins):Health News:Guidebook for Recovery Published by Meditation Master Peter Amato 2Health News:Guidebook for Recovery Published by Meditation Master Peter Amato 3Health News:Range Kleen Partners with Berndes in Red Cross Promotion: Taking Care of Oklahoma 2Health News:DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case 2Health News:DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case 3Health News:DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case 4Health News:Tammy Mushrush Joins ResortQuest Real Estate® and the Dayna Feher Team 2Health News:Sleep Duration Linked to Suicidal Thoughts in People With Insomnia 2
... , , , ALISO ... a premier technology and services resource for pathologists, oncologists and the pharmaceutical ... at the Canaccord Adams 29th Annual Global Growth Conference at 8:00 am ... the InterContinental Boston Hotel, August 11-13, 2009. , , ...
... ... a change in state health policies, will soon be without health says MedicareSupplementPlans.com . ... Los Angeles, CA (Vocus) ... the uninsured over the next four years if there are no changes in state health ...
... ... Managing Mood, Food and Weight ." The book is designed to provide a roadmap for ... mental and physical health. , ... (PRWEB) August 5, 2009 -- Author Sarah Freeman has overcome many challenges when ...
... ... Employers , ... August 5, 2009 -- United Benefit Advisors (UBA), in partnership with the National Association of ... Thursday, Aug. 13, regarding what,s happening now in the national health care reform debate., , ...
... ... PC Magazine and others , ... Destin, FL (PRWEB) August 4, 2009 -- In 1999 Christina Timmons parlayed a background in ... O.I.S. Media, launched MDJobSite.com, http://www.mdjobsite.com , a physician job search website that ...
... , , SEATTLE, Aug. 5 ... Central European/5:30 a.m. Pacific, members of Cell Therapeutics, Inc.,s (CTI) (Nasdaq ... discuss the Company,s 2009 second quarter financial results. , , ... Thursday, August 6, 8:30 a.m. Eastern/2:30 p.m. ...
Cached Medicine News:Health News:Clarient to Present at Canaccord Adams 29th Annual Global Growth Conference on Wednesday, August 12th 2Health News:Number of Californians with No Health Insurance is Rising says MedicareSupplementPlans.com 2Health News:New Book Helps Those with Bipolar Disorder Manage Diets - and Lives 2Health News:UBA offers Free Webinar: NAHU Executive VP and CEO to Discuss Health Reform Bills 2Health News:UBA offers Free Webinar: NAHU Executive VP and CEO to Discuss Health Reform Bills 3Health News:Ten Years Later: O.I.S. Media Leads Physician Job Board Industry with Innovative Technology 2
... Diagnostics Histoplasma DxSelect is intended for qualitatively ... in human serum. The test is indicated ... disease, as an aid in the presumptive ... is not intended for self-testing, and this ...
... Indirect immunofluorescent antibody (IFA) ... and semi-quantitation of human ... Epstein-Barr viral capsid antigen ... ten 12-well slides, FITC ...
... portable, battery-powered, micro-controlled, noninvasive bone growth stimulator ... primary lumbar spinal fusion surgery for one ... been shown in pre-clinical studies to help ... Clinical studies have also shown that individuals ...
... Medical Solutions introduces its new multifunctional ... with intuitive patient data management is ... and urological table. Lithoskop is an ... that covers all applications like lithotripsy, ...
Medicine Products: